Inside the Upgrade
The firm has raised its 2015 EPS estimates from $2.07 to $2.08. FY2016 EPS estimates were increased from $2.21 to $2.30.
The analyst commented: “We expect PFE shares to significantly appreciate over the next 1-2 years based on a better than expected launch of Ibrance, greater appreciation of the durable growth on offer in GEP, further accretive and potentially tax-driven M&A, and the separation of GEP by 2017 at a minimum from the rest of the business.”
Growth and Income
The stock has grown at a steady rate over the last few years and has a dividend yield of about 3.2%. Pfizer stock is perhaps most ideal for income-focused investors that are planning on holding the stock over the long-haul.
Mutual Funds to Watch
|Vanguard Total Stock Mkt Idx
|Vanguard 500 Index
The Bottom Line
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.